SEC Form 4 · accession 0001179110-17-008492
AMAG PHARMACEUTICALS INC. · AMAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julie Krop
Officer — SVP Clinical & Regulatory, CMO
Period of report
Mar 1, 2017
Accepted (ET)
Jun 5, 2017 · 8:42 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000792977
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 1, 2017 | F | 1,108 | $22.85 | D | 35,669 | D | |
| Common StockF3 | Jun 1, 2017 | F | 2,395 | $17.90 | D | 33,274 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,999 restricted stock units on March 1, 2017.
- F2The Reporting Person's Form 4 filed on May 2, 2017 did not take into account the shares withheld on March 1, 2017, and therefore the amount reported in Column 5 on such Form 4 was overstated by 1,108 shares.
- F3Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 7,333 restricted stock units on June 1, 2017.